CAH vs IDXX

Cardinal Health presents a dichotomy of strong growth and fragile liquidity, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits impressive YoY revenue and earnings growth (~19%) and consistently beats analyst estimates, its operational health is hampered by razor-thin profit margins (0.68%) and a concerning current ratio of 0.91. The stock is trading slightly below its intrinsic value of $205.03, but bearish insider activity and a 0/100 technical trend suggest immediate headwinds despite a 'strong_buy' analyst consensus.

IDEXX Laboratories trades at a premium valuation with a P/E of 54.63 and forward P/E of 57.69, reflecting its elite profitability and consistent earnings outperformance. The company has delivered 21 of the last 25 quarters with positive EPS surprises, including a 10% beat in the most recent quarter, underpinning strong execution and demand tailwinds in the veterinary diagnostics space. Despite insider selling activity totaling $40.92M over the past six months, the robust growth trajectory, sector-leading ROE of 64.63%, and favorable peer context—especially against lower-growth but cheaper names like ZTS—support continued outperformance. Price momentum remains strong, with a 1Y return of +62.9%, significantly outpacing the healthcare sector average and validating market confidence in sustained earnings growth.